title: CD14 and TNfa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy.
abstract: OBJECTIVE
  To examine CD14 and TNFalpha gene polymorphisms in early arthritis in relation to clinical outcome.
  
  
  METHODS
  We studied 141 Caucasians who had had early arthritis 10 to 38 years earlier. We analysed CD14 (-159) and TNFalpha (-238, -308, -376) polymorphisms using a novel cycle minisequencing method. DNA pools from 370 Caucasian blood donors served as controls.
  
  
  RESULTS
  CD14 (-159)C-->T allele frequencies were comparable among patients and controls (39% vs 40%). Fifty men and 42 women had recovered while 24 men and six women had chronic spondyloarthropathy (SpA). Mutant T allele frequency was higher in the chronic SpA group than in the recovered group in women (75% vs 32%, relative risk 1.3, 95% confidence limit 1.1 to 1.6, P = 0.011), but not in men (38% vs 44%). All female patients with chronic SpA had CD14 (-159)T allele and none had a possibly protective TNFalpha (-308)G-->A allele.
  
  
  CONCLUSIONS
  Possession of CD14 (-159)T allele does not increase risk of ReA but may increase susceptibility of female patients to development of chronic SpA.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Haartman Institute, University of Helsinki, Finland. heikki.repo@hus.fi
authors.forename: Heikki
authors.initials: H
authors.lastname: Repo
authors.forename: Krista
authors.initials: K
authors.lastname: Anttonen
authors.forename: Sami K
authors.initials: SK
authors.lastname: Kilpinen
authors.forename: Aarno
authors.initials: A
authors.lastname: Palotie
authors.forename: Petri
authors.initials: P
authors.lastname: Salven
authors.forename: Arto
authors.initials: A
authors.lastname: Orpana
authors.forename: Marjatta
authors.initials: M
authors.lastname: Leirisalo-Repo
mesh_terms: D000208:Acute Disease; D000328:Adult; D017668:Age of Onset; D000368:Aged; D016918:Arthritis, Reactive / Q000235:genetics*; D002908:Chronic Disease; D017931:DNA Primers; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D000091402:Prohibitins; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012737:Sex Factors; D025242:Spondylarthropathies / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
chemical_list: D017931:DNA Primers; D018950:Lipopolysaccharide Receptors; C000717331:PHB2 protein, human; D000091402:Prohibitins; D014409:Tumor Necrosis Factor-alpha